Long-term survival of patients with advanced/recurrent carcinoma of cervix and vagina after neoadjuvant treatment with methotrexate, vinblastine, doxorubicin, and cisplatin with or without the addition of molgramostim, and review of the literature

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 25, Issue 6, 2002, Pages 547-551

  Long III, Harry J ^a   Rayson, Sandra ^b   Podratz, Karl C ^a   Abu Ghazaleh, Samir ^c   Suman, Vera ^a   Hartmann, Lynn C ^a   Levitt, Ralph ^d   Nair, Suresh ^e   Hatfield, Alan K ^f   Knost, James A ^g  

^a MAYO CLINIC   (United States)

^b Allan Blair Cancer Centre   (Canada)

^c Sioux Community Cancer Consortium   (United States)

^d MeritCare Hospital   (United States)

^e GEISINGER MEDICAL CENTER   (United States)

^f Carle Cancer Center CCOP   (United States)

^g Illinois Oncol Res Assoc CCOP   (United States)

Author keywords

Cervical cancer; MVAC

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; METHOTREXATE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; VINBLASTINE;

ADULT; AGED; ANOREXIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; FEMALE; GYNECOLOGIC CANCER; HUMAN; LETHARGY; LEUKOPENIA; METASTASIS; NAUSEA; PHASE 3 CLINICAL TRIAL; RECURRENT CANCER; STOMATITIS; TREATMENT OUTCOME; UTERINE CERVIX CANCER; VAGINA CANCER;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CERVIX NEOPLASMS; CISPLATIN; COMBINED MODALITY THERAPY; DOXORUBICIN; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMAN; METHOTREXATE; MIDDLE AGE; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; RECOMBINANT PROTEINS; SUPPORT, U.S. GOV'T, P.H.S.; SURVIVAL ANALYSIS; VAGINAL NEOPLASMS; VINBLASTINE;

EID: 0036898491     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200212000-00002     Document Type: Article

References (13)

1. Parkin DM, Pisani P, Ferlau J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 1993;54:594-606.
2. Cancer statistics 2002. CA Cancer J Clin 2002;52:23-47.
3. Jones WB, Shingleton HM, Russell A, et al. Patterns of care for invasive cervical cancer: Results of a national survey of 1984 and 1990. Cancer 1995;76:1934-47.
4. Perez CA. Uterine cervix. In: Perez CA, Brady LW, ed. Principles and Practice of Radiation Oncology. Philadelphia: JB Lippincott, 1992:1143-202.
5. Omura GA. Current status of chemotherapy for cancer of the cervix. Oncology 1992;6:27-32.
6. Park RC, Thigpen T. Chemotherapy in advanced and recurrent cervical cancer: A review. Cancer 1993;71(suppl 4):1446-50.
7. Vermorken JB. The role of chemotherapy in squamous cell carcinoma of the uterine cervix: A review. Int J Gynecol Cancer 1993;3:129-42.
8. Moore DH, McQuellon RP, Bleesing JA, et al. A randomized phase III study of cisplatin versus cisplatin plus paclitaxel in stage IVB, recurrent or persistent squamous cell carcinoma of the cervix. A Gynecologic Oncology Group Study [Abstract 801]. Proceedings of the American Society of Clinical Oncology 2001;20:201a.
9. Long HJ III, Cross WG, Wieand HS, et al. Phase II trial of methotrexate, vinblastine, doxorubicin, and cisplatin in advanced/recurrent carcinoma of the uterine cervix and vagina. Gynecol Oncol 1995;57:235-9.
10. Murad AM, Medina L, Andrade CA, et al. Phase II open label multicentric trial of MVAC-methotrexate (M), vinblastine (V), doxorubicin (A), and cisplatin (C) plus granulocyte colony stimulating factor (filgastrim) in advanced recurrent cervical carcinoma: Final report [Abstract 774]. Proceedings of the American Society of Clinical Oncology 1995;14:276.
11. Murad AM, Medina L, Andrade CA, et al. Single arm, open label multicentric phase II trial of chemotherapy with methotrexate, vinblastine, doxombicin, and cisplatin (MVAC) plus granulocyte colony stimulating factor (filgrastim) in advanced recurrent cervical cancer [Abstract 877]. Proceedings of the American Society of Clinical Oncology 1994;13.
12. Agarwala N, Nair SG, Ghosh TK. Experience with neoadjuvant methotrexate, vinblastine, adriamycin, cisplatin (MVAC) in locally advanced cervical carcinoma [Abstract 1569]. Proceedings of the American Society of Clinical Oncology 2000;19:396a.
13. Papadimitrou CA, Dimopoulos MA, Giannakoulis N, et al. A phase II trial of methotrexate, vinblastine, doxorubicin, and cisplatin in the treatment of metastatic carcinoma of the uterine cervix. Cancer 1997;79:2391-5.